Barclays’s Inhibikase Therapeutics IKT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$139K Buy
67,839
+48,114
+244% +$109K ﹤0.01% 4170
2026
Q2
$40K Sell
19,725
-1,623
-8% -$2.9K ﹤0.01% 4389
2026
Q1
$35.9K Sell
21,348
-73,447
-77% -$130K ﹤0.01% 4426
2025
Q4
$194K Buy
94,795
+9,217
+11% +$14.7K ﹤0.01% 4340
2025
Q3
$139K Sell
85,578
-24,674
-22% -$42.7K ﹤0.01% 4517
2025
Q2
$215K Buy
110,252
+26,252
+31% +$51.4K ﹤0.01% 4225
2025
Q1
$184K Hold
84,000
– – ﹤0.01% 4092
2024
Q4
$273K Buy
+84,000
New +$210K ﹤0.01% 4155
2023
Q3
– Sell
-11,455
Closed -$41.4K – 4644
2023
Q2
$41.4K Buy
+11,455
New +$42.7K ﹤0.01% 3913

Other funds holding IKT

Barclays's IKT Position: Q3 2026 in Review

Barclays increased its Inhibikase Therapeutics (IKT) stake by 244% in Q3 2026, buying an estimated $109K and bringing the position to 67,839 shares worth $139K. The position accounts for ﹤0.01% of the portfolio, ranked #4170.

Barclays first reported a position in IKT in Q2 2023 and has held it in 9 quarters since. The position peaked at $273K in Q4 2024. 110 funds tracked by Wall St. Rank hold IKT as of Q3 2026.

  • Barclays held 67,839 shares of Inhibikase Therapeutics worth $139K as of Q3 2026.
  • Barclays bought 48,114 Inhibikase Therapeutics shares in Q3 2026, an estimated $109K.
  • Inhibikase Therapeutics made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #4170 holding.
  • Barclays first reported a position in Inhibikase Therapeutics in Q2 2023 and has held it in 9 quarters since.
  • Barclays's Inhibikase Therapeutics position peaked at $273K in Q4 2024.
  • 110 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.